Related references
Note: Only part of the references are listed.Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
Lars Erik Kristensen et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial
Linda Stein Gold et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial
R. B. Warren et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
Xenofon Baraliakos et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States
Martin Bergman et al.
RHEUMATOLOGY AND THERAPY (2021)
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
Kenneth B Gordon et al.
LANCET (2021)
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study
Kim A Papp et al.
LANCET (2021)
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
Iain B. McInnes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Bimekizumab versus Adalimumab in Plaque Psoriasis
R. B. Warren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Bimekizumab versus Secukinumab in Plaque Psoriasis
Kristian Reich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
EFFICACY OF GUSELKUMAB ACROSS BASDAI COMPONENTS IN TREATING AXIAL-RELATED SYMPTOMS OF PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES
F. Behrens et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Psoriasis Prevalence in Adults in the United States
April W. Armstrong et al.
JAMA DERMATOLOGY (2021)
Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
Anjaneya Chimalakonda et al.
DERMATOLOGY AND THERAPY (2021)
Dual inhibition of IL-17A and IL-17F in psoriatic disease
Helena Iznardo et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2021)
Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Psoriatic arthritis for dermatologists
Alice Gottlieb et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2020)
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis
Xintong Li et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study
Abby S. Van Voorhees et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
Christopher T Ritchlin et al.
LANCET (2020)
Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis
Arnold Lee et al.
BIODRUGS (2020)
Efficacy and safety of ixekizumab in a phaseIII, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)
A. S. Paller et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Comparison of Biologics and Oral Treatments for Plaque Psoriasis A Meta-analysis
April W. Armstrong et al.
JAMA DERMATOLOGY (2020)
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review
April W. Armstrong et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Philip J. Mease et al.
LANCET (2020)
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Atul Deodhar et al.
LANCET (2020)
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel -group, randomised, active-controlled, phase 3b trial
Iain B. McInnes et al.
LANCET (2020)
Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F
Ralph Adams et al.
FRONTIERS IN IMMUNOLOGY (2020)
Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis
Adeline Ruyssen-Witrand et al.
RMD OPEN (2020)
Psoriasis: Which therapy for which patient Psoriasis comorbidities and preferred systemic agents
Shivani B. Kaushik et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies
Farzad Alinaghi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study
Elizabeth G. Araujo et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities
Craig A. Elmets et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
Kristian Reich et al.
LANCET (2019)
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
Kristian Reich et al.
LANCET (2019)
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis
Arthur Kavanaugh et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Antidrug antibody formation during tumor necrosis factor α inhibitor treatment of severe psoriatic patients in the real-life practice
Krisztina Herszenyi et al.
POSTEPY DERMATOLOGII I ALERGOLOGII (2019)
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis
C. Ryan et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)
Alice B. Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Dominique Baeten et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon et al.
LANCET (2018)
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Psoriasis pathogenesis and the development of novel targeted immune therapies
Jason E. Hawkes et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)
Jeffrey Crowley et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
Jerry Bagel et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Kristian Reich et al.
LANCET (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
P. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
Dafna Gladman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis Results Through Week Twenty-Four of the GO-VIBRANT Study
Arthur Kavanaugh et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Targeting the interleukin-23/17 axis in axial spondyloarthritis
Ananta Paine et al.
CURRENT OPINION IN RHEUMATOLOGY (2016)
Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis
Silvia Minozzi et al.
EXPERT OPINION ON DRUG SAFETY (2016)
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
K. B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Adalimumab in Patients with Active Noninfectious Uveitis
Glenn J. Jaffe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study
Ian Landells et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Christopher E. M. Griffiths et al.
LANCET (2015)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
M. Lebwohl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Philip J. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis
Muhammad Haroon et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Current Concepts in Psoriatic Arthritis: Pathogenesis and Management
Kurt De Vlam et al.
ACTA DERMATO-VENEREOLOGICA (2014)
Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol
D. van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double- blind randomised placebo- controlled study (RAPID-PsA)
P. J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Antidrug antibodies in psoriasis: a systematic review
L. Hsu et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
Meghna Jani et al.
RHEUMATOLOGY (2014)
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics
Philip J. Mease et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes et al.
LANCET (2013)
Psoriasis Severity and the Prevalence of Major Medical Comorbidity A Population-Based Study
Howa Yeung et al.
JAMA DERMATOLOGY (2013)
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber et al.
GUT (2012)
Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone
Cheryl F. Rosen et al.
RHEUMATOLOGY (2012)
Discovery and mechanism of ustekinumab A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders
Jacqueline M. Benson et al.
MABS (2011)
Golimumab, a New Human Tumor Necrosis Factor α Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis Twenty-Four-Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study
Arthur Kavanaugh et al.
ARTHRITIS AND RHEUMATISM (2009)
Janus kinases in immune cell signaling
Kamran Ghoreschi et al.
IMMUNOLOGICAL REVIEWS (2009)
Angiogenesis drives psoriasis pathogenesis
Regina Heidenreich et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2009)
Guidelines of care for the management of psoriasis and psoriatic arthritis - Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
Etanercept treatment for children and adolescents with plaque psoriasis
Amy S. Paller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment - Results from the induction and maintenance psoriatic arthritis clinical trial 2
D. van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2007)
Quality-of-life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies from a dermatological perspective
PJ Mease et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
K Reich et al.
LANCET (2005)
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2005)
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
C Antoni et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
KA Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)
CE Antoni et al.
ARTHRITIS AND RHEUMATISM (2005)
Quality of life in patients with psoriasis: A systematic literature review
J de Korte et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS (2004)
Etanercept treatment of psoriatic arthritis - Safety, efficacy, and effect on disease progression
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2004)
Determinants of quality of life in patients with psoriasis: A study from the US population
JM Gelfand et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment
RG Langley et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors
PJ Mease
ANNALS OF THE RHEUMATIC DISEASES (2002)
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
PJ Mease et al.
LANCET (2000)